Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate virtually in the following conference in February 2022:
Virtual 11th Annual SVB Leerink Global Healthcare Conference 2022
Dates: Monday, February 14 to Friday, February 18, 2022
Presentation: February 18, 8 a.m. ET / 2 p.m. CET
Presenter: Filippo Petti, CEO
Webcast: A live and archived webcast of the presentation will be available in the Events section of the Celyad Oncology website.
